These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15341478)

  • 1. Potent and orally bioavailable non-peptide antagonists at the human bradykinin B(1) receptor based on a 2-alkylamino-5-sulfamoylbenzamide core.
    Ritchie TJ; Dziadulewicz EK; Culshaw AJ; Müller W; Burgess GM; Bloomfield GC; Drake GS; Dunstan AR; Beattie D; Hughes GA; Ganju P; McIntyre P; Bevan SJ; Davis C; Yaqoob M
    J Med Chem; 2004 Sep; 47(19):4642-4. PubMed ID: 15341478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From bradykinin B2 receptor antagonists to orally active and selective bradykinin B1 receptor antagonists.
    Barth M; Bondoux M; Luccarini JM; Peyrou V; Dodey P; Pruneau D; Massardier C; Paquet JL
    J Med Chem; 2012 Mar; 55(6):2574-84. PubMed ID: 22369198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958.
    Hawkinson JE; Szoke BG; Garofalo AW; Hom DS; Zhang H; Dreyer M; Fukuda JY; Chen L; Samant B; Simmonds S; Zeitz KP; Wadsworth A; Liao A; Chavez RA; Zmolek W; Ruslim L; Bova MP; Holcomb R; Butelman ER; Ko MC; Malmberg AB
    J Pharmacol Exp Ther; 2007 Aug; 322(2):619-30. PubMed ID: 17470643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new class of bradykinin 1 receptor antagonists containing the piperidine acetic acid tetralin core.
    Fotsch C; Biddlecome G; Biswas K; Chen JJ; D'Amico DC; Groneberg RD; Han NB; Hsieh FY; Kamassah A; Kumar G; Lester-Zeiner D; Liu Q; Mareska DA; Riahi BB; Wang YJ; Yang K; Zhan J; Zhu J; Johnson E; Ng G; Askew BC
    Bioorg Med Chem Lett; 2006 Apr; 16(8):2071-5. PubMed ID: 16464576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of potent, orally bioavailable phthalazinone bradykinin B1 receptor antagonists.
    Biswas K; Peterkin TA; Bryan MC; Arik L; Lehto SG; Sun H; Hsieh FY; Xu C; Fremeau RT; Allen JR
    J Med Chem; 2011 Oct; 54(20):7232-46. PubMed ID: 21902230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-Aminobenzophenones as a novel class of bradykinin B1 receptor antagonists.
    Su DS; Lim JL; Tinney E; Wan BL; Murphy KL; Reiss DR; Harrell CM; O'Malley SS; Ransom RW; Chang RS; Pettibone DJ; Yu J; Tang C; Prueksaritanont T; Freidinger RM; Bock MG; Anthony NJ
    J Med Chem; 2008 Jul; 51(13):3946-52. PubMed ID: 18553956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aryl sulfonamides containing tetralin allylic amines as potent and selective bradykinin B1 receptor antagonists.
    Liu Q; Qian W; Li A; Biswas K; Chen JJ; Fotsch C; Han N; Yuan C; Arik L; Biddlecome G; Johnson E; Kumar G; Lester-Zeiner D; Ng GY; Hungate RW; Askew BC
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4593-7. PubMed ID: 20573508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual antagonists of the bradykinin B1 and B2 receptors based on a postulated common pharmacophore from existing non-peptide antagonists.
    Morissette G; Bouthillier J; Marceau F
    Biol Chem; 2006 Feb; 387(2):189-94. PubMed ID: 16497151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel small molecule bradykinin B1 receptor antagonists. Part 3: hydroxyurea derivatives.
    Schnatbaum K; Schaudt M; Stragies R; Pfeifer JR; Gibson C; Locardi E; Scharn D; Richter U; Kalkhof H; Dinkel K; Zischinsky G
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1233-6. PubMed ID: 20036120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclopropylamino acid amide as a pharmacophoric replacement for 2,3-diaminopyridine. Application to the design of novel bradykinin B1 receptor antagonists.
    Wood MR; Schirripa KM; Kim JJ; Wan BL; Murphy KL; Ransom RW; Chang RS; Tang C; Prueksaritanont T; Detwiler TJ; Hettrick LA; Landis ER; Leonard YM; Krueger JA; Lewis SD; Pettibone DJ; Freidinger RM; Bock MG
    J Med Chem; 2006 Feb; 49(4):1231-4. PubMed ID: 16480259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-hydroxy amides as a novel class of bradykinin B1 selective antagonists.
    Wood MR; Schirripa KM; Kim JJ; Kuduk SD; Chang RK; Di Marco CN; DiPardo RM; Wan BL; Murphy KL; Ransom RW; Chang RS; Holahan MA; Cook JJ; Lemaire W; Mosser SD; Bednar RA; Tang C; Prueksaritanont T; Wallace AA; Mei Q; Yu J; Bohn DL; Clayton FC; Adarayn ED; Sitko GR; Leonard YM; Freidinger RM; Pettibone DJ; Bock MG
    Bioorg Med Chem Lett; 2008 Jan; 18(2):716-20. PubMed ID: 18061443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent and orally active ET(A) selective antagonists with 5,7-diarylcyclopenteno[1,2-b]pyridine-6-carboxylic acid structures.
    Yoshizumi T; Takahashi H; Ohtake N; Jona H; Sato Y; Kishino H; Sakamoto T; Ozaki S; Takahashi H; Shibata Y; Ishii Y; Saito M; Okada M; Hayama T; Nishikibe M
    Bioorg Med Chem; 2004 May; 12(9):2139-50. PubMed ID: 15080914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperalgesia in non-obese diabetic (NOD) mice: a role for the inducible bradykinin B1 receptor.
    Gabra BH; Sirois P
    Eur J Pharmacol; 2005 May; 514(1):61-7. PubMed ID: 15878325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of dihydroquinoxalinone acetamides containing bicyclic amines as potent Bradykinin B1 receptor antagonists.
    Chen JJ; Qian W; Biswas K; Viswanadhan VN; Askew BC; Hitchcock S; Hungate RW; Arik L; Johnson E
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4477-81. PubMed ID: 18674903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists.
    Kuduk SD; Di Marco CN; Chang RK; Wood MR; Schirripa KM; Kim JJ; Wai JM; DiPardo RM; Murphy KL; Ransom RW; Harrell CM; Reiss DR; Holahan MA; Cook J; Hess JF; Sain N; Urban MO; Tang C; Prueksaritanont T; Pettibone DJ; Bock MG
    J Med Chem; 2007 Jan; 50(2):272-82. PubMed ID: 17228869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural modification of the highly potent peptide bradykinin B1 receptor antagonist B9958.
    Gera L; Stewart JM; Fortin JP; Morissette G; Marceau F
    Int Immunopharmacol; 2008 Feb; 8(2):289-92. PubMed ID: 18182242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2,3-diaminopyridine bradykinin B1 receptor antagonists.
    Kuduk SD; Ng C; Feng DM; Wai JM; Chang RS; Harrell CM; Murphy KL; Ransom RW; Reiss D; Ivarsson M; Mason G; Boyce S; Tang C; Prueksaritanont T; Freidinger RM; Pettibone DJ; Bock MG
    J Med Chem; 2004 Dec; 47(26):6439-42. PubMed ID: 15588075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent and orally active non-peptide antagonists of the human melanocortin-4 receptor based on a series of trans-2-disubstituted cyclohexylpiperazines.
    Tucci FC; White NS; Markison S; Joppa M; Tran JA; Fleck BA; Madan A; Dyck BP; Parker J; Pontillo J; Arellano LM; Marinkovic D; Jiang W; Chen CW; Gogas KR; Goodfellow VS; Saunders J; Foster AC; Chen C
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4389-95. PubMed ID: 16098742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspartic acid scaffold in bradykinin B1 antagonists.
    Huszár J; Timár Z; Bogár F; Penke B; Kiss R; Szalai KK; Schmidt E; Papp A; Keseru G
    J Pept Sci; 2009 Jun; 15(6):423-34. PubMed ID: 19378355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of novel selective non-peptide kinin B(1) receptor antagonists on mouse pleurisy induced by carrageenan.
    Costa R; Fernandes ES; Menezes-de-Lima O; Campos MM; Calixto JB
    Peptides; 2006 Nov; 27(11):2967-75. PubMed ID: 16914229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.